Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2864
E. Solenov, A. Ershov, G. Baturina, L. E. Katkova, C. Hatzoglou, K. Gourgoulianis, S. Zarogiannis
{"title":"Water and urea transport in benign and malignant pleural mesothelial cells.","authors":"E. Solenov, A. Ershov, G. Baturina, L. E. Katkova, C. Hatzoglou, K. Gourgoulianis, S. Zarogiannis","doi":"10.1183/13993003.CONGRESS-2018.PA2864","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2864","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75344429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2887
Rosen Petkov, T. Mihalova, Y. Yamakova, G. Yankov
{"title":"US guided true cut needle biopsy in patients with malignant mesothelioma","authors":"Rosen Petkov, T. Mihalova, Y. Yamakova, G. Yankov","doi":"10.1183/13993003.congress-2018.pa2887","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2887","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82285041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2871
G. Karpathiou, Sirine Hathroubi, A. Patoir, O. Tiffet, F. Casteillo, C. Brun, Fabien Forest, N. Rahman, M. Péoc'h, M. Froudarakis
{"title":"Differences in the pathological patterns of non-specific pleuritis (NSP).","authors":"G. Karpathiou, Sirine Hathroubi, A. Patoir, O. Tiffet, F. Casteillo, C. Brun, Fabien Forest, N. Rahman, M. Péoc'h, M. Froudarakis","doi":"10.1183/13993003.congress-2018.pa2871","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2871","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85241044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2869
V. Klimenko, A. Reshetov, V. Novik, O. Ivanov, Dmitry Ermakov
The appearance of malignant pleural effusion (PE) is often the first and only symptom of a malignant tumor (MT). In these conditions, the morphological verification of cancer is important for the planning of systemic antitumor treatment. Aims and Objectives: to determine the potential of immunocytochemical methods in the differential diagnosis of malignant PE. Methods: during the period from 2012 to 2017, we observed 234 patients with malignant PE and MT with unknown primary tumor site. All patients underwent a cytomorphological examination of the PE during the diagnosis. 81 patients in thoracic surgery depatment underwent videothorascopy (VTS) with biopsy of the parietal pleura. 93 patients (54 - outpatients) underwent transthoracic needle biopsy of the parietal pleura. On 60 patients (55 - outpatients), an immunocytochemical study of PE was performed. The sensitivity, specificity of the diagnosis in the groups and also its accuracy were assessed. Results: cytomorphological examination of PE was not sufficiently effective. Triplicate cytologic examination detected tumor cells in 76% of cases. Only 16% were able to determine the primary site of the MT. The most effective method was VTS with pleural biopsy: sensitivity 98%, specificity 99%, accuracy 99%. Transthoracic biopsy of the pleura using the Abrams needle showed significantly less diagnostic value: sensitivity 68%, specificity 73%, accuracy 70%. The immunocytochemical method was not inferior to VTS in detecting the primary tumor site: 95% sensitivity, specificity 99,6%, accuracy 95%. Conclusion: an immunocytochemical study is a reliable tool in the diagnosis of malignant PE, and can be succcessfully used in outpatient settings.
{"title":"The use of immunocytochemistry to diagnose the etiology of malignant pleural effusion.","authors":"V. Klimenko, A. Reshetov, V. Novik, O. Ivanov, Dmitry Ermakov","doi":"10.1183/13993003.congress-2018.pa2869","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2869","url":null,"abstract":"The appearance of malignant pleural effusion (PE) is often the first and only symptom of a malignant tumor (MT). In these conditions, the morphological verification of cancer is important for the planning of systemic antitumor treatment. Aims and Objectives: to determine the potential of immunocytochemical methods in the differential diagnosis of malignant PE. Methods: during the period from 2012 to 2017, we observed 234 patients with malignant PE and MT with unknown primary tumor site. All patients underwent a cytomorphological examination of the PE during the diagnosis. 81 patients in thoracic surgery depatment underwent videothorascopy (VTS) with biopsy of the parietal pleura. 93 patients (54 - outpatients) underwent transthoracic needle biopsy of the parietal pleura. On 60 patients (55 - outpatients), an immunocytochemical study of PE was performed. The sensitivity, specificity of the diagnosis in the groups and also its accuracy were assessed. Results: cytomorphological examination of PE was not sufficiently effective. Triplicate cytologic examination detected tumor cells in 76% of cases. Only 16% were able to determine the primary site of the MT. The most effective method was VTS with pleural biopsy: sensitivity 98%, specificity 99%, accuracy 99%. Transthoracic biopsy of the pleura using the Abrams needle showed significantly less diagnostic value: sensitivity 68%, specificity 73%, accuracy 70%. The immunocytochemical method was not inferior to VTS in detecting the primary tumor site: 95% sensitivity, specificity 99,6%, accuracy 95%. Conclusion: an immunocytochemical study is a reliable tool in the diagnosis of malignant PE, and can be succcessfully used in outpatient settings.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91126020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2877
F. Mei, M. Bonifazi, L. Zuccatosta, F. Barbisan, Michele Sediari, S. Gasparini
{"title":"Single-center prospective study on clinical evolution of non-specific pleuritis","authors":"F. Mei, M. Bonifazi, L. Zuccatosta, F. Barbisan, Michele Sediari, S. Gasparini","doi":"10.1183/13993003.CONGRESS-2018.PA2877","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2877","url":null,"abstract":"","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90608432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2882
J. Seymour, I. Psallidas, M. Dobson, N. Rahman
Background: Patients with Malignant Pleural Effusions are offered both inpatient (talc pleurodesis) and outpatient (Indwelling Pleural Catheter (IPC)) treatment options as palliative therapeutic relief. There is a paucity of data regarding the patient experience of either of these treatments. Aim: To evaluate patient satisfaction with both inpatient and outpatient treatment options for MPE. Results: Patients treated with talc pleurodesis (n=18) had an extended inpatient hospital stay (> 3 days) following their procedure. The majority of IPC patients were discharged the same day (n=7/8)). There was a clear preference in the talc pleurodesis group for inpatient treatment, with over half reporting that they would not consider IPC management. Four-fifths of those surveyed believed outpatient management would have either no effect or a negative effect on their quality of life (n=12, 80.0%). Patients who had the IPC reported generally positive outcomes, with the majority experiencing no discomfort and 87.5% of participants rated the overall experience as positive. All but one of the IPC patients surveyed were receiving support at home with their IPC from a domiciliary nurse (n=7, 87.5%) Conclusion: Talc pleurodesis patients report longer inpatient stays than IPC patients, however most would not consider a switch to outpatient management beneficial. The majority of surveyed IPC patients receive assistance at home from a health professional and report positive outcomes. Our results suggest the importance of collecting patients’ experience information for improving MPE management.
{"title":"The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.","authors":"J. Seymour, I. Psallidas, M. Dobson, N. Rahman","doi":"10.1183/13993003.CONGRESS-2018.PA2882","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2882","url":null,"abstract":"Background: Patients with Malignant Pleural Effusions are offered both inpatient (talc pleurodesis) and outpatient (Indwelling Pleural Catheter (IPC)) treatment options as palliative therapeutic relief. There is a paucity of data regarding the patient experience of either of these treatments. Aim: To evaluate patient satisfaction with both inpatient and outpatient treatment options for MPE. Results: Patients treated with talc pleurodesis (n=18) had an extended inpatient hospital stay (> 3 days) following their procedure. The majority of IPC patients were discharged the same day (n=7/8)). There was a clear preference in the talc pleurodesis group for inpatient treatment, with over half reporting that they would not consider IPC management. Four-fifths of those surveyed believed outpatient management would have either no effect or a negative effect on their quality of life (n=12, 80.0%). Patients who had the IPC reported generally positive outcomes, with the majority experiencing no discomfort and 87.5% of participants rated the overall experience as positive. All but one of the IPC patients surveyed were receiving support at home with their IPC from a domiciliary nurse (n=7, 87.5%) Conclusion: Talc pleurodesis patients report longer inpatient stays than IPC patients, however most would not consider a switch to outpatient management beneficial. The majority of surveyed IPC patients receive assistance at home from a health professional and report positive outcomes. Our results suggest the importance of collecting patients’ experience information for improving MPE management.","PeriodicalId":20113,"journal":{"name":"Pleural and Mediastinal Malignancies","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84679904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：